Fibrin and Platelet-targeting Thrombolytic Drug
Exhibitor: Center for Biomedical Research and Development
Booth No: N416
Characteristic
The current thrombolytic therapy or percutaneous coronary intervention (PCI) needs to be combined with anti-platelet drugs for subsequent restenosis or recurrent thrombosis. Antithrombotic drugs in the market are associated with significant bleeding risk and thrombocytopenia. We now have successfully developed a novel antithrombotic drug without these side effects.
Other Products
-
Antithrombotic Drug with Low Risk of Bleeding
-
Bispecific Drugs for Cancers
-
Anti-fibrotic Drug Targeting ECM
-
Modification Platforms for Protein Therapeutics
-
Protein Production and GLP Laboratory
Highest Rated Products
-
Pneumatic Liquid Filling Machine
-
Powder Machine-High Speed Mixer / Granulator
-
Planetary Vacuum Mixer
-
SEMI-AUTOMATIC EYESHADOW PRESS MACHINE
-
2ton Mixing and Melting Tank with Storage Tanks
-
High Speed Mixing Machine
-
In-Line Homogenizer
-
VACUUM EMULSIFY MIXING EQUIPMENT (Bottom Homogenized Series)
-
VACUUM EMULSIFY MIXING EQUIPMENT
-
VACUUM EMULSIFY MIXING EQUIPMENT
-
SuitNifty Scar Gel (Non-Sterile)
-
Natural Marine Collagen
-
TISUCODETM Type II Collagen Capsules
-
Feelife Foaming Wash
-
HUO-FU Collagen Probiotics
-
Feelife Collagen Repair Cream
-
Feelife Intensive Revitalizing Mask
-
Collagen Freeze Crystal Set
-
Life Fusion Collagen Wound Dressing
-
Absorbable Collagen Membrane
-
Lysozyme Hydrochloride
-
Betamethasone Valerate
-
Tadalafil
-
effervescent tablet
-
Etofenamate
-
Hyoscine Butylbromide
-
Betamethasone Sodium Phosphate
-
Carbimazole
-
Betamethasone Dipropionate
-
Ginkgo Dry Extract, Refined and Quantified
